Hamilton AD - Search Results

1

Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.

Sebti SM, Hamilton AD. Sebti SM, et al. Among authors: hamilton ad. Oncogene. 2000 Dec 27;19(56):6584-93. doi: 10.1038/sj.onc.1204146. Oncogene. 2000. PMID: 11426643 Review.

2

Phosphatidylinositol-3-OH kinase/AKT and survivin pathways as critical targets for geranylgeranyltransferase I inhibitor-induced apoptosis.

Dan HC, Jiang K, Coppola D, Hamilton A, Nicosia SV, Sebti SM, Cheng JQ. Dan HC, et al. Oncogene. 2004 Jan 22;23(3):706-15. doi: 10.1038/sj.onc.1207171. Oncogene. 2004. PMID: 14737105

3

ERK couples chronic survival of NK cells to constitutively activated Ras in lymphoproliferative disease of granular lymphocytes (LDGL).

Epling-Burnette PK, Bai F, Wei S, Chaurasia P, Painter JS, Olashaw N, Hamilton A, Sebti S, Djeu JY, Loughran TP. Epling-Burnette PK, et al. Oncogene. 2004 Dec 9;23(57):9220-9. doi: 10.1038/sj.onc.1208122. Oncogene. 2004. PMID: 15516985

4

Protein farnesyltransferase: flexible docking studies on inhibitors using computational modeling.

Guida WC, Hamilton AD, Crotty JW, Sebti SM. Guida WC, et al. Among authors: hamilton ad. J Comput Aided Mol Des. 2005 Dec;19(12):871-85. doi: 10.1007/s10822-005-9030-2. Epub 2006 May 12. J Comput Aided Mol Des. 2005. PMID: 16607571

5

Geranylgeranyltransferase I inhibitors target RalB to inhibit anchorage-dependent growth and induce apoptosis and RalA to inhibit anchorage-independent growth.

Falsetti SC, Wang DA, Peng H, Carrico D, Cox AD, Der CJ, Hamilton AD, Sebti SM. Falsetti SC, et al. Among authors: hamilton ad. Mol Cell Biol. 2007 Nov;27(22):8003-14. doi: 10.1128/MCB.00057-07. Epub 2007 Sep 17. Mol Cell Biol. 2007. PMID: 17875936 Free PMC article.

6

Targeting protein prenylation for cancer therapy.

Berndt N, Hamilton AD, Sebti SM. Berndt N, et al. Among authors: hamilton ad. Nat Rev Cancer. 2011 Oct 24;11(11):775-91. doi: 10.1038/nrc3151. Nat Rev Cancer. 2011. PMID: 22020205 Free PMC article.

7

Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors.

Kazi A, Xiang S, Yang H, Chen L, Kennedy P, Ayaz M, Fletcher S, Cummings C, Lawrence HR, Beato F, Kang Y, Kim MP, Delitto A, Underwood PW, Fleming JB, Trevino JG, Hamilton AD, Sebti SM. Kazi A, et al. Among authors: hamilton ad. Clin Cancer Res. 2019 Oct 1;25(19):5984-5996. doi: 10.1158/1078-0432.CCR-18-3399. Epub 2019 Jun 21. Clin Cancer Res. 2019. PMID: 31227505 Free PMC article.

8

Farnesyltransferase inhibitors are potent lung cancer chemopreventive agents in A/J mice with a dominant-negative p53 and/or heterozygous deletion of Ink4a/Arf.

Zhang Z, Wang Y, Lantry LE, Kastens E, Liu G, Hamilton AD, Sebti SM, Lubet RA, You M. Zhang Z, et al. Among authors: hamilton ad. Oncogene. 2003 Sep 18;22(40):6257-65. doi: 10.1038/sj.onc.1206630. Oncogene. 2003. PMID: 13679864

9

The development of protein farnesyltransferase inhibitors as signaling-based anticancer agents.

Ohkanda J, Blaskovich MA, Sebti SM, Hamilton AD. Ohkanda J, et al. Among authors: hamilton ad. Prog Cell Cycle Res. 2003;5:211-7. Prog Cell Cycle Res. 2003. PMID: 14593715 Review.

10

Geranylgeranyltransferase I inhibitor GGTI-2154 induces breast carcinoma apoptosis and tumor regression in H-Ras transgenic mice.

Sun J, Ohkanda J, Coppola D, Yin H, Kothare M, Busciglio B, Hamilton AD, Sebti SM. Sun J, et al. Among authors: hamilton ad. Cancer Res. 2003 Dec 15;63(24):8922-9. Cancer Res. 2003. PMID: 14695209

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

281 results

Search Page